ERIC DOBMEIER - 19 Jul 2024 Form 4/A Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
19 Jul 2024
Net transactions value
$0
Form type
4/A
Filing time
24 Jul 2024, 20:00:08 UTC
Date Of Original Report
22 Jul 2024
Previous filing
27 Jun 2024
Next filing
01 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +1,231 +25% $0.000000 6,231 19 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (Right to Buy) Award $0 +4,111 $0.000000 4,111 19 Jul 2024 Common Stock 4,111 $44.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.
F2 The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.

Remarks:

This amendment is being filed to correct the number of RSUs and the number of shares subject to the option.